J&J to Pay More Than $1B to Settle Probe: Report

Health Care Reuters

Johnson & Johnson is set to pay more than $1 billion to resolve a U.S. civil investigation into the marketing of its Risperdal antipsychotic drug, Bloomberg News reported on Thursday, citing anonymous sources.

Continue Reading Below

The company reached a deal last week with the U.S. attorney in Philadelphia. The deal does not resolve negotiations over a possible criminal plea, the report said.

Johnson & Johnson spokeswoman Teresa Mueller said the company does not comment on rumors or speculation.

In August, J&J said it reached an agreement related to a misdemeanor charge stemming from the Risperdal investigation, although some issues remained unresolved.  

What do you think?

Click the button below to comment on this article.